SIDEBAR: Genotype and Treatment Outcomes


Get Permission

At the 2011 San Antonio Breast Cancer Symposium, Joyce O’Shaughnessy, MD, described how the genetic profiles of 12 patients with metastatic triple-negative breast were used to guide treatment for metastatic disease

Patient #10 was a 59-year-old African-American woman with primary chemotherapy-refractory recurrent disease over the chest wall. She had not responded to doxorubicin/cyclophosphamide/docetaxel or to cisplatin. Sequencing revealed a KRAS amplicon with KRAS overexpression. Her diffuse disease responded well to pegylated SN-38, the active moiety of irinotecan, raising the hypothesis that irinotecan and SN-38 may be effective in the treatment of chemotherapy-refractory metastatic triple-negative breast cancer that demonstrates RAS pathway activation.

Patient #2 was a 58-year-old Caucasian woman who had transient responses to preoperative doxorubicin/cyclophosphamide/docetaxel, platinum, and bevacizumab. Whole genome sequencing revealed a high-level BRAF amplicon, and she was enrolled on a phase I study of a novel MEK inhibitor plus a novel AKT inhibitor, to which she had a rapid response.

Patient #9 was a 40-year-old Caucasian patient with cancer recurrence in the brain and cervical lymph nodes 18 months after a preoperative regimen of doxorubicin, cyclophosphamide, and paclitaxel, followed by adjuvant cisplatin. She had a strong family history but tested negative for a BRCA germline mutation. In this highly genomically unstable cancer, sequencing revealed multiple mutations and deletions in genes involved in homologous recombination. She underwent brain radiotherapy and had a complete response to iniparib/gemcitabine/carboplatin, “in keeping with numerous DNA repair mutations present in her cancer,” Dr. O’Shaughnessy noted. 

Patient #1 was a 53-year-old African-American woman with metastatic ipsilateral internal mammary and mediastinal nodal recurrence after a pathologic complete response to preoperative chemotherapy 18 months earlier. Sequencing revealed homologous deletion in NF1, plus PTEN deletion. She was treated with a combined PI3K /mTOR inhibitor on a phase I study, and achieved stable disease for 2 months in her very rapidly progressing disease. Progression on the PI3K pathway inhibitor may have been due to activation of the Ras/MAPK pathway in the settings of the NF1 deletion. ■


Related Articles

Next-generation Sequencing in Metastatic Triple-negative Breast Cancer Yields Rewards

The startling molecular heterogeneity of metastatic triple-negative breast cancer is now obvious and helps to explain the poor outcomes observed in this patient subset. Comprehensive genomic and transcriptomic interrogation of metastatic triple-negative breast cancer is elucidating the molecular...

Expert Point of View: Next-gen Sequencing in Metastatic Triple-neg Breast Cancer Yields Rewards

3.5.22_rugo.jpgHope Rugo, MD, of the University of California, San Francisco, commented on Dr. O’Shaughnessy’s presentation on molecular pathways in triple-negative breast cancer at the 2011 San Antonio Breast Cancer Symposium. “The really exciting thing is that we have moved from intrinsic subtyping of breast...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.